KALV Stock Overview
A clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
KalVista Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.09 |
| 52 Week High | US$16.88 |
| 52 Week Low | US$7.39 |
| Beta | 0.91 |
| 11 Month Change | -9.91% |
| 3 Month Change | -24.65% |
| 1 Year Change | 14.40% |
| 33 Year Change | -18.37% |
| 5 Year Change | -29.59% |
| Change since IPO | 20.41% |
Recent News & Updates
Recent updates
KalVista: Upcoming PDUFA, But Not Without Risks
Nov 25Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
Sep 12
KalVista Pharmaceuticals: Looking To Be A Major Player In HAE
Sep 05Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch
Jun 24KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
Feb 14We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Jan 30We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Oct 04We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully
May 02KalVista: Another Setback But The Key Value Driver Is Still In Place
Oct 14Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
Sep 24KalVista Pharmaceticals GAAP EPS of -$0.94
Sep 08KalVista reaches five-month high as rival tumbles on hereditary angioedema
Aug 22KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11
Jul 07Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
May 18Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth
Feb 02We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed
Sep 24We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely
Jul 02Shareholder Returns
| KALV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | 4.3% | 1.6% |
| 1Y | 14.4% | 18.8% | 32.3% |
Return vs Industry: KALV underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: KALV underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| KALV volatility | |
|---|---|
| KALV Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KALV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KALV's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 150 | Ben Palleiko | www.kalvista.com |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial.
KalVista Pharmaceuticals, Inc. Fundamentals Summary
| KALV fundamental statistics | |
|---|---|
| Market cap | US$496.58m |
| Earnings (TTM) | -US$141.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs KALV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KALV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$93.47m |
| Gross Profit | -US$93.47m |
| Other Expenses | US$48.30m |
| Earnings | -US$141.77m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.88 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KALV perform over the long term?
See historical performance and comparison